Study of T-DXd in Chinese breast cancer patients
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have breast cancer that has spread to other parts of the body or cannot be removed by surgery
- Your cancer is either HER2-positive or HER2-low (your doctor will confirm this)
- You have already received at least one treatment for your advanced breast cancer
- You are not pregnant or breastfeeding
- You are willing to start treatment with Trastuzumab Deruxtecan (T-DXd) or have started it within the last 14 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
This study looks at how well the drug trastuzumab deruxtecan works in women with breast cancer that has spread. It is for patients who have already taken this drug.
This study looks at how safe and effective the drug T-DXd (trastuzumab deruxtecan) is for Chinese patients with a specific type of lung cancer that has a HER2 mutation. It helps understand if this treatment works well in real-world settings.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.